JP2023539589A5 - - Google Patents

Info

Publication number
JP2023539589A5
JP2023539589A5 JP2023513309A JP2023513309A JP2023539589A5 JP 2023539589 A5 JP2023539589 A5 JP 2023539589A5 JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023539589 A5 JP2023539589 A5 JP 2023539589A5
Authority
JP
Japan
Application number
JP2023513309A
Other languages
Japanese (ja)
Other versions
JP2023539589A (ja
JPWO2022043895A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/057794 external-priority patent/WO2022043895A2/en
Publication of JP2023539589A publication Critical patent/JP2023539589A/ja
Publication of JP2023539589A5 publication Critical patent/JP2023539589A5/ja
Publication of JPWO2022043895A5 publication Critical patent/JPWO2022043895A5/ja
Pending legal-status Critical Current

Links

JP2023513309A 2020-08-25 2021-08-25 Egfr変異を有する非小細胞肺がんの治療 Pending JP2023539589A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069748P 2020-08-25 2020-08-25
US63/069,748 2020-08-25
PCT/IB2021/057794 WO2022043895A2 (en) 2020-08-25 2021-08-25 Treatment of non-small lung cancer with egfr mutations

Publications (3)

Publication Number Publication Date
JP2023539589A JP2023539589A (ja) 2023-09-15
JP2023539589A5 true JP2023539589A5 (https=) 2024-09-02
JPWO2022043895A5 JPWO2022043895A5 (https=) 2024-09-02

Family

ID=80352814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513309A Pending JP2023539589A (ja) 2020-08-25 2021-08-25 Egfr変異を有する非小細胞肺がんの治療

Country Status (11)

Country Link
US (2) US12528869B2 (https=)
EP (1) EP4204455A4 (https=)
JP (1) JP2023539589A (https=)
KR (1) KR20230053686A (https=)
CN (1) CN116194141A (https=)
AU (1) AU2021330539A1 (https=)
CA (1) CA3192922A1 (https=)
IL (1) IL300854A (https=)
JO (1) JOP20230039A1 (https=)
MX (1) MX2023002362A (https=)
WO (1) WO2022043895A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230174677A1 (en) * 2021-11-16 2023-06-08 Janssen Biotech, Inc. Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL)
US20240317866A1 (en) * 2022-06-30 2024-09-26 Janssen Biotech, Inc. Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer
WO2024108193A2 (en) * 2022-11-18 2024-05-23 Epibiologics, Inc. Degradation of cmet using a bispecific binding agent
CN116284335A (zh) * 2023-03-17 2023-06-23 云南中医药大学 Egfr基因突变体的检测方法及应用
WO2025158277A1 (en) * 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP1766068A4 (en) 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
WO2012142535A2 (en) 2011-04-15 2012-10-18 Esco Corporation Replaceable wear parts for an earth-working roll
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
CN113201073A (zh) * 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MA46852A (fr) 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
WO2020102647A1 (en) 2018-11-15 2020-05-22 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
IL305700A (en) 2021-03-09 2023-11-01 Janssen Biotech Inc Treatment of cancers lacking EFGR-activating mutations

Similar Documents

Publication Publication Date Title
JP2023539589A5 (https=)
BR102021013929A2 (https=)
BR102020016437A2 (https=)
CN306346202S (https=)
CN305797222S (https=)
CN305707421S (https=)
CN306320792S (https=)
CN306319935S (https=)
CN306318942S (https=)
CN306318738S (https=)
CN306318128S (https=)
CN306317562S (https=)
CN305723566S (https=)
CN306302595S (https=)
CN306299448S (https=)
CN305536804S (https=)
CN306298396S (https=)
CN305535387S (https=)
CN306202239S (https=)
CN306201940S (https=)
CN306201041S (https=)
CN306199701S (https=)
CN306194597S (https=)
CN306193571S (https=)
CN306183333S (https=)